<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-141009</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Type 2 diabetes mellitus and obesity: should we treat the obesity or the diabetes?</dc:title>
<dc:description xml:lang="en">In this article, we review the results that can be expected after significant weight loss in patients with type 2 diabetes mellitus. We provide consensus-based documentation supported by the American Diabetes Association, the European Association for the Study of Diabetes, and the International Diabetes Federation on the importance of physical exercise, metabolic-bariatric surgery, and drug therapy. Lastly, we report the results of studies published in the last few years on glucagon-like peptide-1 analogs and the new family of oral drugs known as gliflozins, specifically studies published on dapagliflozin (AU)</dc:description>
<dc:creator>Durán Sanz, Santiago</dc:creator>
<dc:creator>Durán García, Santiago</dc:creator>
<dc:creator>Durán Sanz, Alejandro</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">En este artículo revisamos los resultados que pueden esperarse tras una significativa corrección del exceso de peso en pacientes con diabetes mellitus tipo 2. Aportamos documentación basada en consensos avalados por la American Diabetes Association, la European Association for the Study of Diabetes y la International Diabetes Federation en relación con la importancia del ejercicio físico, la cirugía bariátrica-metabólica y el tratamiento farmacológico. Por último, aportamos nuestra experiencia personal en los estudios publicados en los últimos años referidos a los análogos del péptido similar al glucagón tipo 1 y en relación con la nueva familia de fármacos orales conocida como gliflozinas, concretamente los estudios publicados con dapagliflozina (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);141(supl.2): 14-19, nov. 2013. graf</dc:source>
<dc:identifier>ibc-141009</dc:identifier>
<dc:title xml:lang="es">Diabetes mellitus tipo 2 y obesidad: ¿tratar la obesidad o la diabetes?</dc:title>
<dc:subject>^d3946^s22012</dc:subject>
<dc:subject>^d7182^s22011</dc:subject>
<dc:subject>^d7182^s22078</dc:subject>
<dc:subject>^d3950</dc:subject>
<dc:subject>^d23862</dc:subject>
<dc:subject>^d22231</dc:subject>
<dc:subject>^d6105^s22073</dc:subject>
<dc:subject>^d24572</dc:subject>
<dc:subject>^d9951^s22067</dc:subject>
<dc:subject>^d50567^s32387</dc:subject>
<dc:subject>^d9951^s22044</dc:subject>
<dc:subject>^d7127^s22012</dc:subject>
<dc:subject>^d50911^s22006</dc:subject>
<dc:subject>^d4071</dc:subject>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d3946^s22067</dc:subject>
<dc:subject>^d3946^s22044</dc:subject>
<dc:subject>^d28600</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9951^s22012</dc:subject>
<dc:subject>^d33150</dc:subject>
<dc:subject>^d36032^s22067</dc:subject>
<dc:subject>^d7127^s22044</dc:subject>
<dc:subject>^d7182^s22073</dc:subject>
<dc:subject>^d51221</dc:subject>
<dc:type>article</dc:type>
<dc:date>201311</dc:date>
</metadata>
</record>
</ibecs-document>
